Devyser Diagnostics AB (FRA:OL0) EBIT: €2.78 Mil (TTM As of Mar. 2026)


FRA:OL0 Devyser Diagnostics AB FRA:OL0
77 GF Score
Price €7.59
GF Value €14.06
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Devyser Diagnostics AB EBIT?

Devyser Diagnostics AB FRA:OL0 77 EBIT is €2.78 Mil as of Mar. 2026. GuruFocus rates FRA:OL0 with a GF Score™ of 77/100 and a GF Value™ of €14.06 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Devyser Diagnostics AB's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was €0.47 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was €2.78 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Devyser Diagnostics AB's annualized ROC % for the quarter that ended in Mar. 2026 was 1.77%. Devyser Diagnostics AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 15.56%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Devyser Diagnostics AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 2.20%.


Devyser Diagnostics AB  (FRA:OL0) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Devyser Diagnostics AB's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=0.928 * ( 1 - 34.07% )/( (34.165 + 34.843)/ 2 )
=0.6118304/34.504
=1.77 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Devyser Diagnostics AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1.892/( ( (7.609 + max(4.788, 0)) + (7.306 + max(4.614, 0)) )/ 2 )
=1.892/( ( 12.397 + 11.92 )/ 2 )
=1.892/12.1585
=15.56 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(5.219 + 3.4 + 1.388) - (1.875 + 0 + 3.344)
=4.788

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(5.338 + 3.881 + 0.492) - (1.81 + 0 + 3.287)
=4.614

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Devyser Diagnostics AB's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=2.781/126.340
=2.20 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Devyser Diagnostics AB EBIT Related Terms


Devyser Diagnostics AB EBIT Historical Data

* Premium members only.

The historical data trend for Devyser Diagnostics AB's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Devyser Diagnostics AB EBIT Chart

Devyser Diagnostics AB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only -2.04 -4.75 -4.79 -4.70 0.04

Devyser Diagnostics AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.32 0.52 0.13 1.66 0.47

FRA:OL0 vs ABT, SYK, MDT: EBIT Comparison

For the Medical Devices subindustry, Devyser Diagnostics AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Devyser Diagnostics AB EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Devyser Diagnostics AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Devyser Diagnostics AB's EV-to-EBIT falls into.


FRA:OL0
77GF Score
Devyser Diagnostics AB FRA:OL0
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Devyser Diagnostics AB EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.78 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €2.78 Mil mean?
Devyser Diagnostics AB (FRA:OL0) has a EBIT of €2.78 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Devyser Diagnostics AB.
Is Devyser Diagnostics AB's EBIT too high?
Devyser Diagnostics AB's current EBIT is €2.78 Mil. Overall, Devyser Diagnostics AB has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Devyser Diagnostics AB's EBIT compare to ABT and SYK?
Devyser Diagnostics AB's EBIT of €2.78 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Devyser Diagnostics AB. Devyser Diagnostics AB's current EBIT is €2.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Devyser Diagnostics AB stock overvalued right now?
Based on GuruFocus' analysis, Devyser Diagnostics AB (FRA:OL0) is currently considered Significantly Undervalued. The stock's GF Value™ is €14.06, compared to a current price of €7.59 — trading 46% below its estimated fair value. The current EBIT is €2.78 Mil. Devyser Diagnostics AB's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Devyser Diagnostics AB (FRA:OL0), the current EBIT is €2.78 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Devyser Diagnostics AB (FRA:OL0) Overvalued in 2026?

Based on GuruFocus' analysis, Devyser Diagnostics AB stock appears to be undervalued. The current stock price of €7.59 is trading 46% below its estimated GF Value™ of €14.06. GuruFocus considers Devyser Diagnostics AB to be Significantly Undervalued.

Key valuation signals for FRA:OL0:

  • EBIT: €2.78 Mil
  • GF Value™: €14.06 vs. price of €7.59 (46% below fair value)
  • GF Score™: 77/100 with 2 warning signs

No single metric tells the full story. See the FRA:OL0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Devyser Diagnostics AB Business Description

Other Exchanges DVYSR:Sweden
Address Branningevagen 12, Arsta, SWE, 120 54
Devyser Diagnostics AB is engaged in the development, manufacture, and sale of kits for genetic testing in routine diagnostic laboratories. The products are used for advanced genetic testing in the hereditary disease, oncology, and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up.
77GF Score

Get the complete analysis for FRA:OL0

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.59
Price
€14.06
GF Value